PreveCeutical Medical is an early stage biotech with ample risk in a nascent development pipeline. Nonetheless, the Company has made progress with its development projects, demonstrating the ability of the scientific team to execute on the R&D agenda.
Highest priority on the Company’s agenda is a non-opioid pain treatment compound based on cannabinoids and administered through a proprietary nose-to-brain drug delivery system. Called the Sol-Gel system, it is intended to deliver a therapeutic compound to a targeted diseased site at a slow, controlled rate.
Another project in the development pipeline involves the identification of peptides and proteins in the venom of Caribbean blue scorpion, which will be used for the purposes of engineering ‘nature identical’ compounds. Synthesizing compounds identical to the natural venom is expected to facilitate more commercially viable formulations.
Given the progress the scientific team has made thus far in executing against the Company’s research and development agenda, within the next year we expect the achievement of certain objectives in the Sol-Gel drug delivery system and the blue scorpion venom peptide identification program. The scenario would be ideal for an early stage biotechnology company that benefits from raising capital as new value is created through its R&D program. If we are correct in our expectations, such quantifiable progress should facilitate additional partnering and capital raising actions at higher valuation levels.
Additional details are available in a full nine-page report by clicking on the image below:
Please note the important disclosures and disclaimers at the end of all Crystal Equity Research reports.